TAGRISSO (osimertinib) is an EGFR TKI indicated for adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).1
About the T790M mutation
The majority of cases of TKI-acquired resistance are due to the EGFR-T790M mutation8
To determine T790M mutation status and begin second-line treatment, it is critical to be aware of and identify each potential sign of progression.
It is important to bear in mind that at the point of progression in EGFR+ NSCLC, no two patients are the same.
The majority of patients progress on
1st-line EGFR TKI therapy after 8−14 months9
TAGRISSO is specifically designed to target the EGFR T790M mutation1
TAGRISSO is a treatment for adult patients with locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer (NSCLC)1
Following 1st-line EGFR TKI therapy, acquired resistance may be due to the T790M mutation. TAGRISSO – a 3rd-generation, irreversible inhibitor – selectively targets both EGFRm and EGFR T790M resistance mutations, whilst exhibiting lower activity than 1st-generation TKIs against wild-type EGFR.1
Mechanism of action (MoA)
In the MoA video below, learn how TAGRISSO acts by binding irreversibly to specific EGFR mutations, blocking the activity of the EGFR.